Boston Scientific stock jumped Wednesday after the medtech giant easily beat Wall Street's fourth-quarter expectations and its own guidance.

CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in Q4, exceeding guidance.

Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.

Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...

Boston is in for some quick-hitting snow and potentially some more messy weather this weekend. WBZ-TV meteorologists Jacob ...

Nasdaq provides Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluation. Financial analysts and individual investors use PE Ratio and PEG ratios to determine the financial ...

A Globe survey of Boston ... charging stations, but rather the private sector,” Janet Domenitz, executive director of MASSPIRG said. The federal funds were “intended to fill gaps in the system ...

“In that first couple of months, I had four or five people use it,” Rabbitt says, who installed his system in February ... America’s EV charging deserts have all but disappeared, yet the ...

Republican lawmakers reached out to the Auditor this week to request a hard look at the state’s overflowing shelter system, and seemed pleasantly surprised to discover an audit is already underway.

The patent analysis site CarMoses spotted a recent GM patent application for a system that is capable of charging and discharging simultaneously. The patent describes a "charging system" with a ...

BT has abandoned its scheme to turn green street cabinets into electric vehicle (EV) charging points having completed only one of the 60,000 conversions it initially said it was aiming for.